(S)-tert-butyl 1-(3-(2-(5-(dimethylcarbamoyl)-2-fluorophenyl)thiazole-4-carboxamido)pyridin-4-yl)piperidin-3-ylcarbamate | 1270034-57-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (S)-tert-butyl 1-(3-(2-(5-(dimethylcarbamoyl)-2-fluorophenyl)thiazole-4-carboxamido)pyridin-4-yl)piperidin-3-ylcarbamate
• 英文别名: tert-butyl N-[(3S)-1-[3-[[2-[5-(dimethylcarbamoyl)-2-fluorophenyl]-1,3-thiazole-4-carbonyl]amino]pyridin-4-yl]piperidin-3-yl]carbamate
• CAS: 1270034-57-5
• 化学式: C₂₈H₃₃FN₆O₄S
• 分子量: 568.672
• InChiKey: VBRAVEZNPCPIDA-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  40
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  145
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
  申请人：Wang Xiaojing

  公开号：US20110059961A1

  公开（公告）日：2011-03-10

  The invention relates to compounds of formula (I) which are useful as kinase inhibitors, more specifically useful as PIM kinase inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same, either alone or in combination, to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  这项发明涉及到式(I)的化合物，这些化合物可用作激酶抑制剂，更具体地用作PIM激酶抑制剂，因此可用作癌症治疗药物。该发明还涉及到包括这些化合物的组合物，更具体地是包括这些化合物的药物组合物，以及使用这些组合物的方法，无论是单独使用还是结合使用，用于治疗各种癌症和高增殖性疾病，以及使用这些化合物进行体外、体内和体内诊断或治疗哺乳动物细胞或相关病理条件的方法。
• US8435976B2
  申请人：——

  公开号：US8435976B2

  公开（公告）日：2013-05-07
• [EN] 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PYRIDIN-3-YL-CARBOXAMIDE 4-SUBSTITUÉ ET PROCÉDÉS D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011029802A1

  公开（公告）日：2011-03-17

  The invention relates to compounds of Formula (I) which are useful as kinase inhibitors, more specifically useful as PIM kinase inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same, either alone or in combination, to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.